Hexadecylphosphocholine (miltefosine) Has Broad-spectrum Fungicidal Activity and is Efficacious in a Mouse Model of Cryptococcosis

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2006 Jan 27

PMID 16436691

Citations 43

Authors

Fred Widmer

Lesley C Wright

Daniel Obando

Rosemary Handke

Ranjini Ganendren

David H Ellis

Tania C Sorrell

Affiliations

Soon will be listed here.

Abstract

The alkyl phosphocholine drug miltefosine is structurally similar to natural substrates of the fungal virulence determinant phospholipase B1 (PLB1), which is a potential drug target. We determined the MICs of miltefosine against key fungal pathogens, correlated antifungal activity with inhibition of the PLB1 activities (PLB, lysophospholipase [LPL], and lysophospholipase-transacylase [LPTA]), and investigated its efficacy in a mouse model of disseminated cryptococcosis. Miltefosine inhibited secreted cryptococcal LPTA activity by 35% at the subhemolytic concentration of 25 microM (10.2 microg/ml) and was inactive against mammalian pancreatic phospholipase A2 (PLA2). At 250 microM, cytosolic PLB, LPL, and LPTA activities were inhibited by 25%, 51%, and 77%, respectively. The MICs at which 90% of isolates were inhibited (MIC90s) against Candida albicans, Candida glabrata, Candida krusei, Cryptococcus neoformans, Cryptococcus gattii, Aspergillus fumigatus, Fusarium solani, Scedosporium prolificans, and Scedosporium apiospermum were 2 to 4 microg/ml. The MICs of miltefosine against Candida tropicalis (n = 8) were 2 to 4 microg/ml, those against Aspergillus terreus and Candida parapsilosis were 8 microg/ml (MIC90), and those against Aspergillus flavus (n = 8) were 2 to 16 microg/ml. Miltefosine was fungicidal for C. neoformans, with rates of killing of 2 log units within 4 h at 7.0 microM (2.8 microg/ml). Miltefosine given orally to mice on days 1 to 5 after intravenous infection with C. neoformans delayed the development of illness and mortality and significantly reduced the brain cryptococcal burden. We conclude that miltefosine has broad-spectrum antifungal activity and is active in vivo in a mouse model of disseminated cryptococcosis. The relatively small inhibitory effect on PLB1 enzyme activities at concentrations exceeding the MIC by 2 to 20 times suggests that PLB1 inhibition is not the only mechanism of the antifungal effect.

Citing Articles

Progress in antileishmanial drugs: Mechanisms, challenges, and prospects.

Zhang H, Yan R, Liu Y, Yu M, He Z, Xiao J PLoS Negl Trop Dis. 2025; 19(1):e0012735.

PMID: 39752369 PMC: 11698350. DOI: 10.1371/journal.pntd.0012735.

Synthesis of Keratin Nanoparticles Extracted from Human Hair through Hydrolysis with Concentrated Sulfuric Acid: Characterization and Cytotoxicity.

Silva O, Rossin A, Lima A, Valente A, Garcia F, Nakamura C Materials (Basel). 2024; 17(15).

PMID: 39124423 PMC: 11313240. DOI: 10.3390/ma17153759.

Strategies of Pharmacological Repositioning for the Treatment of Medically Relevant Mycoses.

Gomez-Gaviria M, Contreras-Lopez L, Aguilera-Dominguez J, Mora-Montes H Infect Drug Resist. 2024; 17:2641-2658.

PMID: 38947372 PMC: 11214559. DOI: 10.2147/IDR.S466336.

Miltefosine: A Repurposing Drug against Mucorales Pathogens.

Xisto M, Rollin-Pinheiro R, Rochetti V, Castro-Almeida Y, Borba-Santos L, Santos-Freitas G J Fungi (Basel). 2023; 9(12).

PMID: 38132767 PMC: 10744482. DOI: 10.3390/jof9121166.

Oral delivery of brain-targeted miltefosine-loaded alginate nanoparticles functionalized with polysorbate 80 for the treatment of cryptococcal meningitis.

Spadari C, Lanser D, Araujo M, De Jesus D, Lopes L, Gelli A J Antimicrob Chemother. 2023; 78(4):1092-1101.

PMID: 36881722 PMC: 10319950. DOI: 10.1093/jac/dkad053.

References

Cox G, McDADE H, Chen S, Tucker S, Gottfredsson M, Wright L . Extracellular phospholipase activity is a virulence factor for Cryptococcus neoformans. Mol Microbiol. 2000; 39(1):166-75. DOI: 10.1046/j.1365-2958.2001.02236.x. View

Birch M, Robson G, Law D, Denning D . Evidence of multiple extracellular phospholipase activities of Aspergillus fumigatus. Infect Immun. 1996; 64(3):751-5. PMC: 173833. DOI: 10.1128/iai.64.3.751-755.1996. View

Geilen C, Haase R, Buchner K, Wieder T, Hucho F, REUTTER W . The phospholipid analogue, hexadecylphosphocholine, inhibits protein kinase C in vitro and antagonises phorbol ester-stimulated cell proliferation. Eur J Cancer. 1991; 27(12):1650-3. DOI: 10.1016/0277-5379(91)90438-j. View

Chen S, Wright L, Santangelo R, Muller M, Moran V, Kuchel P . Identification of extracellular phospholipase B, lysophospholipase, and acyltransferase produced by Cryptococcus neoformans. Infect Immun. 1997; 65(2):405-11. PMC: 174609. DOI: 10.1128/iai.65.2.405-411.1997. View

Sage L, Hambrey P, Werchola G, Mellors A, Tizard I . Lysophospholipase 1 in Trypanosoma brucei. Tropenmed Parasitol. 1981; 32(4):215-20. View

Husain S, Munoz P, Forrest G, Alexander B, Somani J, Brennan K . Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis. 2004; 40(1):89-99. DOI: 10.1086/426445. View

Lux H, Hart D, Parker P, Klenner T . Ether lipid metabolism, GPI anchor biosynthesis, and signal transduction are putative targets for anti-leishmanial alkyl phospholipid analogues. Adv Exp Med Biol. 1996; 416:201-11. DOI: 10.1007/978-1-4899-0179-8_33. View

Howden B, Slavin M, Schwarer A, Mijch A . Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur J Clin Microbiol Infect Dis. 2003; 22(2):111-3. DOI: 10.1007/s10096-002-0877-z. View

Sindermann H, Croft S, Engel K, BOMMER W, Eibl H, Unger C . Miltefosine (Impavido): the first oral treatment against leishmaniasis. Med Microbiol Immunol. 2003; 193(4):173-80. DOI: 10.1007/s00430-003-0201-2. View

10.

Meletiadis J, Mouton J, Meis J, Verweij P . In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother. 2002; 47(1):106-17. PMC: 149034. DOI: 10.1128/AAC.47.1.106-117.2003. View

11.

Geilen C, Wieder T, REUTTER W . Hexadecylphosphocholine inhibits translocation of CTP:choline-phosphate cytidylyltransferase in Madin-Darby canine kidney cells. J Biol Chem. 1992; 267(10):6719-24. View

12.

Kontoyiannis D, Lionakis M, Lewis R, Chamilos G, Healy M, Perego C . Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis. 2005; 191(8):1350-60. DOI: 10.1086/428780. View

13.

Chen S, Muller M, Zhou J, Wright L, Sorrell T . Phospholipase activity in Cryptococcus neoformans: a new virulence factor?. J Infect Dis. 1997; 175(2):414-20. DOI: 10.1093/infdis/175.2.414. View

14.

DE HAAS G, van Oort M, Dijkman R, Verger R . Phospholipase A2 inhibitors: monoacyl, monoacylamino-glycero-phosphocholines. Biochem Soc Trans. 1989; 17(2):274-6. DOI: 10.1042/bst0170274. View

15.

Geilen C, Haase A, Wieder T, Arndt D, Zeisig R, REUTTER W . Phospholipid analogues: side chain- and polar head group-dependent effects on phosphatidylcholine biosynthesis. J Lipid Res. 1994; 35(4):625-32. View

16.

BLIGH E, Dyer W . A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959; 37(8):911-7. DOI: 10.1139/o59-099. View

17.

Mirbod F, Banno Y, Ghannoum M, Ibrahim A, Nakashima S, Kitajima Y . Purification and characterization of lysophospholipase-transacylase (h-LPTA) from a highly virulent strain of Candida albicans. Biochim Biophys Acta. 1995; 1257(2):181-8. DOI: 10.1016/0005-2760(95)00072-k. View

18.

Breiser A, Kim D, Fleer E, Damenz W, Drube A, Berger M . Distribution and metabolism of hexadecylphosphocholine in mice. Lipids. 1987; 22(11):925-6. DOI: 10.1007/BF02535556. View

19.

Ganendren R, Widmer F, Singhal V, Wilson C, Sorrell T, Wright L . In vitro antifungal activities of inhibitors of phospholipases from the fungal pathogen Cryptococcus neoformans. Antimicrob Agents Chemother. 2004; 48(5):1561-9. PMC: 400561. DOI: 10.1128/AAC.48.5.1561-1569.2004. View

20.

Croft S, Seifert K, Duchene M . Antiprotozoal activities of phospholipid analogues. Mol Biochem Parasitol. 2003; 126(2):165-72. DOI: 10.1016/s0166-6851(02)00283-9. View